Skip to main content

Alnylam Licenses Kreutzer-Limmer Patents to Shanghai GenePharma

NEW YORK (GenomeWeb News) – Alnylam Pharmaceuticals announced today that it has granted a non-exclusive, worldwide license to Shanghai GenePharma, allowing the Chinese siRNA supplier to manufacture and sell RNAi products and services covered by Alnylam-owned patents for research purposes.
 
Alnylam owns exclusive rights to many RNAi structural properties and applications — for instance, in mammalian cells — under the Kreutzer-Limmer patent family. This license allows Shanghai GenePharma to provide these research tools to the pharmaceutical and research community in China and beyond.
 
As of last October, Alnylam had licensed its intellectual property to three other research product suppliers in Asia and 15 worldwide. That number has now climbed to more than 16 license agreements, according to Alnylam Vice President of Business Development Jason Rhodes.
 
“Providing this license to Shanghai GenePharma represents our first business transaction in China, which is regarded as having one of the fastest growing life science markets in the world,” Rhodes said in a statement.
 
Financial terms of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.